MOASC has a new address! Please make changes to your directory. |
|
Mail and Letters
MOASC
PO Box 400606
Hesperia, CA 92340
|
|
Packages and Magazines
MOASC
17240 Olive Street, Box 400606
Hesperia, CA 92340
|
|
- Southern California Permanente Medical Group seeks Urologic Oncologists in Riverside and San Bernardino.
|
|
- Subscribe to MOASC’s Job Board for more opportunities!
|
|
-
A Treatment for Relapsed/Refractory Advanced Renal Cell Carcinoma clinical webinar will be presented this Thursday, August 25 at 5:30pm PDT. Find out about the latest therapeutic option in the rapidly evolving management of relapsed/refractory advanced renal cell carcinoma post >2 systemic therapies. For the first time, prospective phase 3 data are available for heavily pretreated subjects, including post checkpoint inhibitors.
|
|
-
Spotlight On Clinical Oncology, Saturday, August 27, 2022, 1:00pm to 7:00pm-PDT. In partnership with the UCI Hematology/Oncology Fellowship Program and Faculty, MOASC has organized a LIVE learning symposia, which will cover timely updates in clinical practice, research & development, technology and drug advancements in the field of medical oncology. Oncology experts will discuss innovations in the diagnosis and management of complex oncology issues, including highlights from the Annual ASCO meeting. Your deadline to register is on Wednesday, August 24, 2022.
|
|
-
MOASC presents Treatment of Unresectable Stage 3 Non-Small Cell Lung Cancer, Wednesday August 31, 6pm PDT. This event is part of MOASC’s monthly, virtual Lung Webinar Series. These, 60-minute, educational webinars provide updates in clinical practice, research & development, technology & drug advancements in the treatment of Lung Cancer.
|
|
- ANCO with apos;s invites you to their Hematology/Oncology Career Forum, August 27, 2022, 1-3:30pm InterContinental.
|
|
-
California health officials confirmed they are avoiding using the term "monkeypox" and will now refer to it as "mpox" or “MPX,” as per the World Health Organization.
-
SB 250, authored by Senator Richard Pan, M.D., will comprehensively reform the prior authorization process, resulting in less time spent on administrative work, increased access to necessary care for patients and a restoration of the physician-patient relationship in medical decision-making.
-
A powerful labor union and California’s hospitals are closing in on a deal that would allow hospitals to put off meeting seismic safety standards that will cost them tens of billions of dollars in exchange for significant boosts in minimum pay for certain health care workers. The proposal, however, has set off alarm bells for five unions representing hundreds of thousands of workers in the state’s health care industry. They quickly assembled a coalition that fired off a letter Tuesday to state leaders to strongly oppose a legislative deal that would extend seismic safety standards set to go into effect for California’s hospitals in 2030.
|
|
-
On August 25, 11:00am(PT) – 11:30am(PT) CMS Administrator, Chiquita Brooks-LaSure, will review the impacts and highlight implementation of the Inflation Reduction Act. This call is open to national and local stakeholders and will provide an opportunity to learn how you can partner with CMS to implement the new law.
|
|
-
Follow the links below for the key takeaways, as provided by Janssen Pharmaceuticals, for the 2023 Medicare Physician Fee Schedule Proposed Rule, highlighting changes to the Quality Payment Program (QPP) & Non QPP parts of the rule.
|
|
-
HHS is accepting comments on a proposed rule that takes an expansive view of Section 1557 of the Affordable Care Act to prevent discriminatory practices in health care. Some health care organizations would have to hire a compliance coordinator, antidiscrimination policies would have to be clearly stated and available to people with limited English proficiency, and the rule would apply to clinicians who accept Medicare Part B.
|
|
-
The final rules governing resolution of payment disputes for unexpected out-of-network medical bills under the No Surprises Act, have been released by HHS and the Departments of Labor and Treasury.
|
|
-
Landmark revisions were implemented in the Evaluation and Management (E/M) office visit section in 2021, the CPT® Editorial Panel has also approved additional revisions to the rest of the E/M code section effective Jan. 1, 2023.
|
|
-
The Food and Drug Administration published, in the Federal Register, their Proposed Rules to amend regulations governing the format of the National Drug Code (NDC). This action, if finalized, will standardize the format of all NDCs. Specifically, all NDCs will be required to be 12 digits in length with 3 distinct segments and 1 uniform format.
|
|
-
44% of cancer deaths in 2019 and 42% of healthy years lost were linked to potentially modifiable risk factors such as smoking, according to a study published in The Lancet. The study, based on cancer death and disability data from 204 countries, found that risk-attributable cancer deaths rose 20.4% globally from 2010 to 2019.
|
|
-
Few cancer centers have price transparency. Just 20 of 63 National Cancer Institute-designated cancer centers in the US are fully compliant with a federal hospital price transparency rule that took effect last year, according to a study published in JAMA Surgery. About two-thirds of the hospitals offered some information on negotiated rates by August 2021, but less than one-third met the full requirements.
|
|
-
A HealthEdge survey of more than 300 health insurance executives showed managing costs was their top challenge this year, and nearly half of respondents believe improving claims accuracy and increasing interoperability will help them effectively mitigate administrative costs. Increasing quality, improving provider relationships and member satisfaction, and meeting regulatory requirements were among the top goals of health insurance leaders, and more than half of them plan to make major investments in innovation, boost engagement strategies, bring their business and IT organization toward common objectives and modernize technology to achieve these goals.
|
|
-
Some insurers appear to be using primary care reimbursement rates to calculate national Qualifying Payment Amount payments to specialists for out-of-network care. The No Surprises Act requires that QPA calculations be based on payment data from the same or similar specialty in the same geographic region, and a survey found many insurers are contracting with primary care providers for services they rarely if ever perform.
|
|
-
UnitedHealthcare will begin migrating some physicians to an updated commercial fee schedule beginning in October 2022. The fee schedule update, slated to occur in several phases between October 2022 and January 2023, will move physicians on older fee schedules dating back to 2008 to a new 2020 UHC commercial fee schedule based on 2020 CMS RVU values.
|
|
-
How coronavirus vaccines saved oncologist-patient relationship. The COVID-19 pandemic has delayed cancer screening, diagnosis and treatment and impeded the physical and emotional interactions that are an integral part of cancer care. But now COVID-19 vaccines, high filtration masks and oral antivirals are bringing down some of those barriers so patients with cancer can again feel safe and valued, writes oncologist Jalal Baig.
|
|
-
Data from EMRs alone is not of high enough quality to predict survival of patients with metastatic cancer for research purposes, but combining EMR data with cancer registry data improves accuracy, according to a report in JCO Clinical Cancer Informatics. The researchers found using EMR data alone led to significant overestimates of survival, but accuracy improved when data from the Stanford Cancer Registry/California Cancer Registry was added.
|
|
MOASC is pleased to acknowledge and thank the following company for their generous support of your association. Please welcome and thank them when they call, e-mail and come to your office.
-
Exelixis (Silver) is a biotechnology company founded in 1994, which strives to accelerate the discovery, development and commercialization of new medicines. They are supplementing their existing therapeutic assets with targeted business development activities and internal drug discovery — all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer.
|
|
-
Bluebird bio's lentiviral vector gene therapy Zynteglo, or betibeglogene autotemcel, gained FDA approval as a treatment for beta-thalassemia.
|
|
-
Daiichi-Sankyo, Inc. informed that the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. This is the first drug approved for HER2-mutant NSCLC.
|
|
-
Gilead Sciences, Inc. announced recent updates to the NCCN Guidelines® for Breast Cancer regarding sacituzumab govitecan-hziy (Trodelvy®) in two types of metastatic breast cancer. In adult patients with metastatic triple-negative breast cancer (TNBC) who received at least two prior therapies, with at least one line for metastatic disease, sacituzumab govitecan is now a category 1 preferred regimen.
|
|
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
|
|
|
|
|
|
|
